BioRock Ventures — Seed & Series A VC Firm
BioRock Ventures is a Seed, Series A venture capital firm investing in Healthcare. The firm has 7 portfolio companies in our records.
- Portfolio
- 7 companies on record
- Partners
- 1 listed
- Stage
- Seed, Series A
- Sectors
- Healthcare
- Check size
- Not in our records
- AUM
- Not in our records
Last verified: 2026-10-27
Seed, Series A
7+ companies
1 partner
Investment Thesis
Seed VC fund investing in startups developing best-in-class medicines and novel FDA-regulated therapeutic drugs. The firm explicitly backs private life science companies across angel, seed, Series A, and later stages.
How BioRock Ventures invests
BioRock Ventures is a vc firm. The firm invests at the Seed, Series A stages, with a focus on Healthcare.
BioRock Ventures has backed 7 companies in our records, including Immusoft, Vidya Therapeutics, AN2.
Partners & Team
Mary is founding managing partner of BioRock Ventures in the Bay Area, CA. Mary began two decades of operating experience as a therapeutics startup founder in Boston. She moved to roles leading negotiations, business and technical evaluations for M&A and licensing deals as well as strategy roles at large and medium pharmaceuticals companies like Johnson & Johnson and Forest, now Allergan/Abbvie, in NYC. She also has served as consulting CBO for several dozen early stage ventures around the world. She began venture investing a decade ago where she helped form and put first money into two new companies which each had IPO exits valued over $1 Billion. Mary is a Kauffman Fellow, earned an MBA from MIT Sloan, a PhD from Princeton University and an undergraduate degree from Yale University.
Industry Focus
Invests In
Portfolio Companies (7)
Other
Immusoft
Develops engineered B cell therapies to produce therapeutic proteins in patients
Vidya Therapeutics
Exit, acquired
AN2
Primmune Therapeutics
Develops immune-system-based therapies
PTM Therapeutics, Inc.
Therapeutics company
Vaxcyte
Develops broad-spectrum vaccines
AN2 Therapeutics
Develops small-molecule therapeutics from a boron chemistry platform
- •Raising at Seed, Series A? You're squarely in their sweet spot.
- •Lead with your fit in Healthcare — the sectors they actively back.
- •warm intro preferred
- •Address your outreach to a specific partner, such as Mary Wheeler, Managing Director.
- •A warm introduction beats a cold email. Get matched and request an intro.
Featured In
Browse More Investors
Fundraising resources
Frequently Asked Questions
See if BioRock Ventures is a match for your startup
Upload your pitch deck to see how well you match with BioRock Ventures and 10,000+ other investors.
Ask your AI assistant about this investor: connect InvestorMatch to Claude or ChatGPT
Is this your profile? Request a correction or removal